ARWR: SHASTA-3 and SHASTA-4 Data Presented at ESC 2026
On August 30, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) announced the presentation of results from the SHASTA-3 and SHASTA-4 trials of...
98 Views
ARWR: Acquires PRV for sNDA Submission for Plozasiran in sHTG
On August 4, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the third quarter of fiscal year 2026 that ended June...
114 Views
ARWR: SHASTA-3 and SHASTA-4 Hit on All Endpoints Including 100% Reduction in Acute Pancreatitis in High-Risk Patients
On July 22, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) announced positive results for the SHASTA-3 and SHASTA-4 trials of plozasiran in patients...
92 Views
ARWR: Multiple Important Clinical Readouts in 2H26
On May 7, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the second quarter of fiscal year 2026 that ended March 31,...
124 Views
ARWR: Strong Start for REDEMPLO Commercialization
On February 5, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the first quarter of fiscal year 2026 that ended...
258 Views